These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 32502198)

  • 1. Correction: Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
    Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
    PLoS One; 2020; 15(6):e0234581. PubMed ID: 32502198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: HIV-1C proviral DNA for detection of drug resistance mutations.
    Huruy K; Mulu A; Liebert UG; Maier M
    PLoS One; 2018; 13(11):e0207079. PubMed ID: 30383834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence.
    Thierry E; Lebourgeois S; Simon F; Delelis O; Deprez E
    Sci Rep; 2017 Oct; 7(1):14067. PubMed ID: 29070877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.
    Malet I; Ambrosio FA; Subra F; Herrmann B; Leh H; Bouger MC; Artese A; Katlama C; Talarico C; Romeo I; Alcaro S; Costa G; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2018 May; 73(5):1158-1166. PubMed ID: 29373677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.
    Mulu A; Maier M; Liebert UG
    J Transl Med; 2015 Dec; 13():377. PubMed ID: 26626277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.
    Brenner BG; Wainberg MA
    Virus Res; 2017 Jul; 239():1-9. PubMed ID: 27422477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.
    Theys K; Abecasis A; Libin P; Gomes PT; Cabanas J; Camacho RJ; Van Laethem K
    J Clin Virol; 2015 Sep; 70():120-127. PubMed ID: 26305833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
    Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
    Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
    Moreno S; Berenguer J
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
    Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA
    mBio; 2017 Apr; 8(2):. PubMed ID: 28377526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout.
    Osman N; Mesplède T; Quashie PK; Oliveira M; Zanichelli V; Wainberg MA
    J Antimicrob Chemother; 2015 Oct; 70(10):2810-5. PubMed ID: 26142476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of HIV integrase resistance mutation using in silico approaches.
    da Silva HHSA; Pereira N; Brandão L; Crovella S; Moura R
    Infect Genet Evol; 2019 Mar; 68():10-15. PubMed ID: 30453083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.
    Oliveira M; Mesplède T; Quashie PK; Moïsi D; Wainberg MA
    AIDS; 2014 Mar; 28(6):813-9. PubMed ID: 24463394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection.
    Temesgen Z; Talwani R; Rizza SA
    Drugs Today (Barc); 2014 Jan; 50(1):7-14. PubMed ID: 24524102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms of action, pharmacology and interactions of dolutegravir].
    Ribera E; Podzamczer D
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():2-8. PubMed ID: 25858605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.